Ad-26-COV-2-S

N/A

Report date: 2023/06/07 14:08:15

Base Information

Drug NameAd-26-COV-2-S
Drug Alias NameAd26COVS1Ad26.COV2.SAd26 COV2 SJCOVDENJNJ-78436735 +[6] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/02/27
Country/TerritoryBelgiumUnited StatesUkraine +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesAspen PharmaJanssen Pharmaceuticals IncJanssen Pharmaceutical Kk +[6] 
Inactive CompaniesJanssen-Cilag International NvWits Health Consortium (Pty) LtdInstituto De Investigación Marqués De Valdecilla +[4] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsRejection of renal transplantation

Other Information

ATC CodeJ07B
Related LinksN/A